Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer
暂无分享,去创建一个
Tanja Fehm | Nina Ditsch | Dieter Niederacher | Alfons Meindl | Sarah Schott | Christoph Engel | Marion Kiechle | Ulrike Faust | Andrea Gehrig | Bernhard H F Weber | Christine Fischer | Eric Hahnen | Rita K Schmutzler | Kerstin Rhiem | T. Fehm | A. Meindl | R. Schmutzler | M. Kiechle | N. Ditsch | B. Wappenschmidt | C. Fischer | C. Engel | E. Hahnen | G. Emons | G. Borck | K. Kast | K. Rhiem | N. Maass | S. Schott | N. Arnold | A. Gehrig | D. Niederacher | P. Wimberger | B. Auber | J. Horváth | J. Hauke | N. Rahner | Nils Rahner | Barbara Wappenschmidt | S. Zachariae | Nicolai Maass | Norbert Arnold | Karin Kast | Jan Hauke | Britta Bluemcke | Verena Zarghooni | Natalie Herold | Michael Braun | Nicola Dikow | Clemens Mueller-Reible | Guntram Borck | Nikolaus de Gregorio | Caroline Scholz | Bernd Auber | Raymonda Varon-Manteeva | Dorothee Speiser | Judit Horvath | Nadine Lichey | Pauline Wimberger | Sylvia Stark | Gunter Emons | Silke Zachariae | M. Braun | N. de Gregorio | D. Speiser | N. Dikow | B. Weber | V. Zarghooni | C. Scholz | N. Herold | S. Stark | U. Faust | Britta Bluemcke | C. Mueller-Reible | Raymonda Varon-Manteeva | Nadine Lichey
[1] Nina Ditsch,et al. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. , 2011, Deutsches Arzteblatt international.
[2] Sean V Tavtigian,et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Klijn,et al. Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers , 2004, Clinical Cancer Research.
[4] A. Russo,et al. Hereditary ovarian cancer. , 2009, Critical reviews in oncology/hematology.
[5] Sue Healey,et al. ENIGMA—Evidence‐based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes , 2012, Human mutation.
[6] C. Gilks,et al. Ovarian carcinoma pathology and genetics: recent advances. , 2009, Human pathology.
[7] A. Jakubowska,et al. Hereditary ovarian cancer in Poland , 2003 .
[8] R. Gershoni-baruch,et al. BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer , 1999, European Journal of Human Genetics.
[9] L. Forétova,et al. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer , 2008, BMC Cancer.
[10] A. Spurdle,et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.
[11] D. Easton,et al. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface , 2013, British Journal of Cancer.
[12] F. Couch,et al. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] Brigitte Rack,et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Jakubowska,et al. Hereditary ovarian cancer in Poland. , 2004, International journal of cancer.
[15] Thorsten Kühn,et al. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms , 2013, Senologie.
[16] J. D. Thompson,et al. BRCA1 mutations in a population-based sample of young women with breast cancer. , 1996, The New England journal of medicine.
[17] F. Couch,et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.
[18] D. Evans,et al. BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries , 2010, Journal of Medical Genetics.
[19] M. King,et al. Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.
[20] B. Modan,et al. Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status. , 2000, Gynecologic oncology.
[21] N Risch,et al. Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994, Cancer.
[22] Barbara L. Smith,et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. , 1996, The New England journal of medicine.
[23] A Gulino,et al. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] T. Dörk,et al. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer , 2001, British Journal of Cancer.
[25] E. Schröck,et al. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium , 2013, Journal of Medical Genetics.
[26] A. Meindl,et al. Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer , 2014, International journal of cancer.
[27] K. Claes,et al. BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families , 2004, British Journal of Cancer.
[28] E. Gross,et al. A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers , 1999, Human mutation.
[29] J Chang-Claude,et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.
[30] Karl W Broman,et al. BayesMendel: an R Environment for Mendelian Risk Prediction , 2004, Statistical applications in genetics and molecular biology.
[31] Giovanni Parmigiani,et al. Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Barry Rosen,et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.
[33] Stephen W Duffy,et al. A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.